高危人群感染 SARS-CoV-2 奥密克戎变异株后使用索托维单抗治疗出现耐药相关突变。
Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant.
机构信息
Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
Division of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
出版信息
JAMA. 2022 Sep 20;328(11):1104-1107. doi: 10.1001/jama.2022.13854.
Abstract
This study investigates whether resistance-associated mutations develop after treatment with sotrovimab in high-risk patients infected with the SARS-CoV-2 Omicron variant.
摘要
本研究旨在调查在感染 SARS-CoV-2 奥密克戎变异株的高危患者中使用 sotrovimab 治疗后是否会出现耐药相关突变。
相似文献
1
Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant.高危人群感染 SARS-CoV-2 奥密克戎变异株后使用索托维单抗治疗出现耐药相关突变。
JAMA. 2022 Sep 20;328(11):1104-1107. doi: 10.1001/jama.2022.13854.
2
Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use.使用索托维单抗后新冠病毒德尔塔变异株中的耐药突变
N Engl J Med. 2022 Apr 14;386(15):1477-1479. doi: 10.1056/NEJMc2120219. Epub 2022 Mar 9.
3
COVID-19 Updates: Monoclonal Antibodies for COVID-19.新冠疫情最新消息：用于治疗新冠的单克隆抗体
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16.
4
Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab.接受索托维单抗治疗患者中新冠病毒奥密克戎变体的耐药突变
Clin Microbiol Infect. 2022 Sep;28(9):1297-1299. doi: 10.1016/j.cmi.2022.05.002. Epub 2022 May 17.
5
Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.在感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）α变体的高危患者中，接受巴瑞替尼单药治疗后出现E484K突变
Viruses. 2021 Aug 19;13(8):1642. doi: 10.3390/v13081642.
6
Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series.在奥密克戎风暴时期索特罗维单抗的疗效：病例系列研究。
Viruses. 2022 Dec 30;15(1):102. doi: 10.3390/v15010102.
7
An EUA for sotrovimab for treatment of COVID-19.索托维单抗用于治疗新冠肺炎的紧急使用授权。
Med Lett Drugs Ther. 2021 Jun 28;63(1627):97-xx98.
8
[Sotrovimab in controlling SARS-CoV-2 infection].[索托维单抗在控制新型冠状病毒2感染中的作用]
Pol Merkur Lekarski. 2022 Feb 22;50(295):48-50.
9
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.
10
Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?索托维单抗对新冠病毒（SARS-CoV-2）变异株失去中和效力，但仍具有临床疗效：抗新冠单克隆抗体是否被过早摒弃？
J Infect Public Health. 2024 Sep;17(9):102512. doi: 10.1016/j.jiph.2024.102512. Epub 2024 Aug 7.
引用本文的文献
1
Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study.奈玛特韦/利托那韦用于高危人群新冠治疗的成本效益分析：一项建模研究
Open Forum Infect Dis. 2025 Mar 26;12(4):ofaf187. doi: 10.1093/ofid/ofaf187. eCollection 2025 Apr.
2
Drupacine as a potent SARS-CoV-2 replication inhibitor .德鲁帕辛作为一种有效的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）复制抑制剂。
Biosaf Health. 2024 Sep 3;6(5):270-278. doi: 10.1016/j.bsheal.2024.09.001. eCollection 2024 Oct.
3
A Longitudinal Description of the Health-Related Quality of Life Among Individuals at High Risk After SARS-CoV-2 Infection: A Dutch Multicenter Observational Cohort Study.SARS-CoV-2感染后高危个体健康相关生活质量的纵向描述：一项荷兰多中心观察性队列研究。
Open Forum Infect Dis. 2025 Jan 30;12(2):ofaf055. doi: 10.1093/ofid/ofaf055. eCollection 2025 Feb.
4
SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants.来自瑞德西韦治疗非住院参与者的3期松树研究的SARS-CoV-2耐药性分析。
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0123824. doi: 10.1128/aac.01238-24. Epub 2024 Dec 19.
5
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.免疫功能低下且持续性感染患者体内具有抗药性的 SARS-CoV-2 变种的出现，降低了对这些抗病毒药物的敏感性。
Nat Commun. 2024 Sep 18;15(1):7999. doi: 10.1038/s41467-024-51924-3.
6
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.在患有持续性感染的免疫功能低下患者中，出现了对抗病毒药物敏感性降低的可传播的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体。
medRxiv. 2024 Jun 18:2024.06.14.24308523. doi: 10.1101/2024.06.14.24308523.
7
Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model.遗传耐药屏障：中和单克隆抗体在非人类灵长类动物模型中针对 SARS-CoV-2 疗效的关键参数。
J Virol. 2024 Jul 23;98(7):e0062824. doi: 10.1128/jvi.00628-24. Epub 2024 Jun 20.
8
A Robust Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T- and B-Cell Response Is Associated With Early Viral Clearance in SARS-CoV-2 Omicron-Infected Immunocompromised Individuals.在 SARS-CoV-2 奥密克戎感染免疫功能低下个体中，强大的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）特异性 T 细胞和 B 细胞反应与早期病毒清除相关。
J Infect Dis. 2024 Oct 16;230(4):e860-e871. doi: 10.1093/infdis/jiae306.
9
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.SARS-CoV-2 对单克隆抗体和小分子药物的耐药性。
Cell Chem Biol. 2024 Apr 18;31(4):632-657. doi: 10.1016/j.chembiol.2024.03.008.
10
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.245例免疫功能低下患者中针对新冠病毒变异株的单克隆抗体疗法的临床和病毒学结果：一项多中心前瞻性队列研究
Clin Infect Dis. 2024 Jun 14;78(6):1514-1521. doi: 10.1093/cid/ciae026.
Zotero 插件